These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 36859556)
1. A peek behind the curtain in the diagnosis and management of COVID‑19‑Associated Mucormycosis (CAM). Osman NA; Anwar MM; Singh B; Gupta GK; Rabie AM J Egypt Public Health Assoc; 2023 Mar; 98(1):4. PubMed ID: 36859556 [TBL] [Abstract][Full Text] [Related]
2. Multidisciplinary approach in diagnosis and treatment of COVID-19-associated mucormycosis: a description of current reports. Gogineni H; So W; Mata K; Greene JN Egypt J Intern Med; 2022; 34(1):58. PubMed ID: 35911783 [TBL] [Abstract][Full Text] [Related]
4. Epidemiology, clinical presentation and management of COVID-19 associated mucormycosis: A single centre experience from Pune, Western India. Dravid A; Kashiva R; Khan Z; Bande B; Memon D; Kodre A; Mane M; Pawar V; Patil D; Kalyani S; Raut P; Bapte M; Saldanha C; Chandak D; Patil T; Reddy S; Bhayani K; Suresh L; Dillibabu V; Srivastava S; Khandelwal S; More S; Shakeel A; Pawar M; Nande P; Harshe A; Kadam S; Hallikar S; Kamal N; Andrabi D; Bodhale S; Raut A; Chandrashekhar S; Raman C; Mahajan U; Joshi G; Mane D Mycoses; 2022 May; 65(5):526-540. PubMed ID: 35212032 [TBL] [Abstract][Full Text] [Related]
5. Mucormycosis in COVID-19 patients: predisposing factors, prevention and management. Rudrabhatla PK; Reghukumar A; Thomas SV Acta Neurol Belg; 2022 Apr; 122(2):273-280. PubMed ID: 34820787 [TBL] [Abstract][Full Text] [Related]
6. Mucormycosis and diabetes in the times of COVID-19: A Mumbai-based observational study. Hinduja ARA; Tambe RR; Giri PA; Sunil S; Limaye H; Kalpana G J Family Med Prim Care; 2022 Oct; 11(10):6107-6114. PubMed ID: 36618183 [TBL] [Abstract][Full Text] [Related]
7. Diabetes and Covid Associated Mucormucormycosis-A Cross Sectional Study in Kilpauk Medical College. Pradeepkumar V J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443380 [TBL] [Abstract][Full Text] [Related]
8. Challenges in the diagnosis and treatment of mucormycosis. Skiada A; Lass-Floerl C; Klimko N; Ibrahim A; Roilides E; Petrikkos G Med Mycol; 2018 Apr; 56(suppl_1):93-101. PubMed ID: 29538730 [TBL] [Abstract][Full Text] [Related]
9. Breaking the Mold: A Review of Mucormycosis and Current Pharmacological Treatment Options. Riley TT; Muzny CA; Swiatlo E; Legendre DP Ann Pharmacother; 2016 Sep; 50(9):747-57. PubMed ID: 27307416 [TBL] [Abstract][Full Text] [Related]
10. Diabetic ketoacidosis and coronavirus disease 2019-associated mucormycosis: a case report. Monroig V; Tarquinio KM J Med Case Rep; 2022 Oct; 16(1):400. PubMed ID: 36316719 [TBL] [Abstract][Full Text] [Related]
11. Mucormycosis in the COVID-19 Environment: A Multifaceted Complication. Sharma R; Kumar P; Rauf A; Chaudhary A; Prajapati PK; Emran TB; Gonçalves Lima CM; Conte-Junior CA Front Cell Infect Microbiol; 2022; 12():937481. PubMed ID: 35923801 [TBL] [Abstract][Full Text] [Related]
12. Results from a national survey on COVID-19-associated mucormycosis in Germany: 13 patients from six tertiary hospitals. Seidel D; Simon M; Sprute R; Lubnow M; Evert K; Speer C; Seeßle J; Khatamzas E; Merle U; Behrens C; Blau IW; Enghard P; Haas CS; Steinmann J; Kurzai O; Cornely OA Mycoses; 2022 Jan; 65(1):103-109. PubMed ID: 34655486 [TBL] [Abstract][Full Text] [Related]
13. COVID-19-Associated Mucormycosis (CAM): Case-Series and Global Analysis of Mortality Risk Factors. Riad A; Shabaan AA; Issa J; Ibrahim S; Amer H; Mansy Y; Kassem I; Kassem AB; Howaldt HP; Klugar M; Attia S J Fungi (Basel); 2021 Oct; 7(10):. PubMed ID: 34682258 [TBL] [Abstract][Full Text] [Related]
15. Pulmonary mucormycosis in the aftermath of critical COVID-19 in an immunocompromised patient: Mind the diagnostic gap. Crone CG; Helweg-Larsen J; Steensen M; Arendrup MC; Helleberg M J Mycol Med; 2022 Mar; 32(1):101228. PubMed ID: 34826672 [TBL] [Abstract][Full Text] [Related]
16. Mucormycosis: The hidden and forgotten disease. Darwish RM; AlMasri M; Al-Masri MM J Appl Microbiol; 2022 Jun; 132(6):4042-4057. PubMed ID: 35156271 [TBL] [Abstract][Full Text] [Related]
17. Posaconazole or isavuconazole as sole or predominant antifungal therapy for COVID-19-associated mucormycosis. A retrospective observational case series. Soman R; Chakraborty S; Joe G Int J Infect Dis; 2022 Jul; 120():177-178. PubMed ID: 35405351 [TBL] [Abstract][Full Text] [Related]
18. Rhino-orbital mucormycosis following COVID-19 in previously non-diabetic, immunocompetent patients. Nair AG; Adulkar NG; D'Cunha L; Rao PR; Bradoo RA; Bapaye MM; Kothari A; Dave TV; Shinde CA Orbit; 2021 Dec; 40(6):499-504. PubMed ID: 34338124 [TBL] [Abstract][Full Text] [Related]
19. Why is mucormycosis more difficult to cure than more common mycoses? Katragkou A; Walsh TJ; Roilides E Clin Microbiol Infect; 2014 Jun; 20 Suppl 6():74-81. PubMed ID: 24279587 [TBL] [Abstract][Full Text] [Related]
20. Is Serum Ferritin an Early Marker for COVID-19-Associated Mucormycosis? Dp I; Yadhav Ml K; Gs C Cureus; 2023 Mar; 15(3):e36734. PubMed ID: 37123703 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]